Try our mobile app

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

Published: 2022-03-22 13:05:00 ET
<<<  go to CRDF company page

SAN DIEGO, March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that CEO Mark Erlander, Ph.D., has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 AM - 5:00 PM EDT.

Cardiff Oncology is a clinical-stage biotechnology company and our mission is to develop new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Our investigational drug, onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics. We are assessing tumor genomics and using our expertise in biomarker technology to rapidly evaluate patient response to treatment. (PRNewsfoto/Cardiff Oncology, Inc.)

Details on the presentation can be found below.

Presentation Format:

Fireside Chat

Presentation Date:

March 28, 2022

Presentation Time:

2:30 PM ET

In addition to the fireside chat, Dr. Erlander will also provide a pre-recorded overview of Cardiff Oncology's clinical and corporate strategy. The pre-recorded presentation will be available throughout the duration of the conference, which will be streamed live on M-Vest. To attend, sign up to become an M-Vest member here.

A replay of the fireside chat will be available by visiting the "Events" section on the investor page of the Cardiff Oncology website after the conference's conclusion.

About Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com

Cardiff Oncology Contact: Vicki Kelemen Chief Operating Officer 858-952-7652 vkelemen@cardiffoncology.com 

Investor Contact: Joyce AllaireLifeSci Advisors 212-915-2569 jallaire@lifesciadvisors.com 

Media Contact: Amy Jobe, Ph.D. LifeSci Communications 315-879-8192 ajobe@lifescicomms.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-llc-301507797.html

SOURCE Cardiff Oncology, Inc.